TRX Gold Corporation (TRX)

关于

Tissue Regenix Group plc is a United Kingdom-based medical devices company in the field of regenerative medicine. The Company is engaged in the development of regenerative products to make replacement body parts using biological (human & animal) materials, using platform technologies in the field of tissues engineering and regenerative medicine. The Company has developed decellularisation (dCELL) technology, which removes DNA and other cellular material from tissue leaving an acellular scaffold which is not rejected by the patient’s body. The applications of dCELL address critical clinical needs such as wound care, heart valve replacement and knee repair. The company has developed DermaPure, a decellularized human dermis product, which replaces human dermis with human dermis, to most closely approximate the structure and function of the native tissue it is replacing.